A carregar...
Biomarkers of immune checkpoint inhibitor efficacy in cancer
Immune checkpoint inhibitor–based therapies that target ctla-4, PD-1, or the PD-1 ligand PD-L1 have received approval in Canada and many parts of the world for the treatment of melanoma, renal cell cancer, urothelial cancer, classical Hodgkin lymphoma, and non-small-cell lung cancer. However only a...
Na minha lista:
| Publicado no: | Curr Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Multimed Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7194000/ https://ncbi.nlm.nih.gov/pubmed/32368180 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.5549 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|